Section of Advanced Heart Failure and Transplant Cardiology, University of Alabama at Birmingham, Birmingham, Alabama.
Division of Cardiovascular Diseases, Spectrum Health, Grand Rapids, Michigan.
JACC Heart Fail. 2017 Oct;5(10):703-711. doi: 10.1016/j.jchf.2017.06.014.
This study sought to evaluate predictors of stroke during left ventricular assist device (LVAD) support from data available prior to implantation, and quantify stroke-related morbidity and mortality.
Stroke is a major complication after LVAD. Pre-implant factors that influence stroke are not well understood.
We evaluated all patients in INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) who were implanted with continuous flow LVADs from May 1, 2012, to March 31, 2015. Pre-operative risk factors for stroke and stroke incidence, morbidity, and mortality were analyzed.
During the study period, 7,112 patients underwent continuous flow LVAD placement. Median follow-up was 9.79 months (range 0.02 to 34.96 months). Of all patients, 752 (10.57%) had at least 1 stroke, with an incidence rate of 0.123 strokes per patient-year. A total of 447 (51.38%) strokes were ischemic and 423 (48.62%) were hemorrhagic. Patients with hemorrhagic stroke had worse survival than those with ischemic strokes (30-day survival: 45.3% vs. 80.7%; p < 0.001). Of patients with a first stroke, 13% had a second stroke. Pre-implant predictors of stroke were female sex (hazard ratio [HR]: 1.51; 95% confidence interval [CI]: 1.25 to 1.82; p < 0.001), pre-implant systolic blood pressure (HR: 1.01; 95% CI: 1.00 to 1.01; p = 0.002), heparin-induced thrombocytopenia (HR: 3.68; 95% CI: 1.60 to 8.47; p = 0.002), intra-aortic balloon pump (HR: 1.21; 95% CI: 1.01 to 1.46; p = 0.043), and primary cardiac diagnosis (ischemic/other/unknown) (p = 0.040).
Despite improvements in LVAD technology, stroke-related morbidity and mortality is substantial. Further investigation is necessary to decrease the risk of this devastating complication.
本研究旨在评估左心室辅助装置(LVAD)植入前数据中与卒中相关的预测因素,并量化卒中相关发病率和死亡率。
卒中是 LVAD 后发生的主要并发症。影响卒中的植入前因素尚不清楚。
我们评估了 2012 年 5 月 1 日至 2015 年 3 月 31 日期间接受连续血流 LVAD 植入的 INTERMACS(机械循环支持机构间注册)中的所有患者。分析了卒中的术前危险因素以及卒中的发生率、发病率和死亡率。
在研究期间,7112 例患者接受了连续血流 LVAD 植入。中位随访时间为 9.79 个月(范围 0.02 至 34.96 个月)。所有患者中,752 例(10.57%)至少发生 1 次卒中,患者年卒中发生率为 0.123 次。共有 447 例(51.38%)为缺血性卒中,423 例(48.62%)为出血性卒中。出血性卒中患者的生存率低于缺血性卒中患者(30 天生存率:45.3% vs. 80.7%;p < 0.001)。首次卒中患者中,13%发生第二次卒中。卒中的术前预测因素为女性(HR:1.51;95%置信区间 [CI]:1.25 至 1.82;p < 0.001)、植入前收缩压(HR:1.01;95%CI:1.00 至 1.01;p = 0.002)、肝素诱导的血小板减少症(HR:3.68;95%CI:1.60 至 8.47;p = 0.002)、主动脉内球囊泵(HR:1.21;95%CI:1.01 至 1.46;p = 0.043)和主要心脏诊断(缺血性/其他/未知)(p = 0.040)。
尽管 LVAD 技术不断改进,但卒中相关发病率和死亡率仍然很高。需要进一步研究以降低这种灾难性并发症的风险。